Xgeva

Do you want to link to this Other Site and leave Amgen.co.kr?

YOU ARE NOW LEAVING AMGEN KOREA'S WEB SITE. Amgen Korea takes takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

XGEVA® Injection

  • Product Name (Korean) 엑스지바®주(데노수맙)
  • Product Name (English) Xgeva® Inj, (denosumab)
  • Active Ingredient (Korean) 데노수맙
  • Active Ingredient (English) denosumab
  • API content 120 mg/1.7 mL
  • Excipients Sorbitol, glacial acetic acid, sodium hydroxide, water for injection
  • Treatment Treatment of serious bone problems in patients with bone metastases from solid tumors and multiple myeloma.
  • Indications
    1. Reduction of the risk for developing skeletal-related events in patients with bone metastases from solid tumors and multiple myeloma. Skeletal-related events refers to pathological fractures, radiation to bone, spinal cord compression, and bone surgery.
    2. Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
  • XGEVA® Production information
PRODUCTS